Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–2 of 2 results
Advanced filters: Author: Kathryn M. Cappell Clear advanced filters
  • Chimeric antigen receptor (CAR) T cells have dramatically improved the outcomes of patients with certain relapsed and/or refractory haematological malignancies. Owing to the promising short-term survival outcomes achieved, long-term data on both safety and survival are becoming increasingly relevant. In this Review, the authors describe the available long-term follow-up data from early studies testing the safety and efficacy of receiving CAR T cells targeting CD19 as well as more recent data on BCMA-targeted CAR T cells in patients with relapsed and/or refractory multiple myeloma.

    • Kathryn M. Cappell
    • James N. Kochenderfer
    Reviews
    Nature Reviews Clinical Oncology
    Volume: 20, P: 359-371
  • Chimeric antigen receptor (CAR) T cell therapies are generating substantial excitement and have been approved for the treatment of various haematological malignancies. All approved CARs consist of an extracellular antigen-binding domain linked to an intracellular region containing a costimulatory domain and a T cell activation domain. A key question is whether the CD28-derived and 4-1BB-derived costimulatory domains used in current commercial CAR T cell products are associated with different cellular and clinical effects. Herein, Cappell and Kochenderfer provide an overview of CD28 and 4-1BB costimulatory pathways and compare the outcomes observed in preclinical and clinical studies with CARs incorporating either costimulatory domain.

    • Kathryn M. Cappell
    • James N. Kochenderfer
    Reviews
    Nature Reviews Clinical Oncology
    Volume: 18, P: 715-727